

NATIONAL INSTITUTES OF HEALTH (NIH)
Recombinant DNA Advisory Committee (RAC)

125th Meeting

Bethesda Marriott Suites
Bethesda, MD

June 7-9, 2011

Tuesday, June 7, 2011

11:00 AM

Call to Order and Opening Remarks

John Zaia, M.D., RAC Chair

Tab 2653 For Your Information
 Notice of Meeting
 Conflict of Interest Guidance

11:05 AM

Discussion of Human Gene Transfer Protocol #1104-1106 entitled: *A Phase I Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D03 DNA and MVA/HIV62B Vaccines in Healthy, HIV-1-Uninfected Vaccinia Naïve Adult Participants*

PI: Susan Buchbinder, M.D., San Francisco Department of Public Health, San Francisco, CA
Slide Presentation

RAC Reviewers: Andrew Badley, M.D.
 Jeffrey Kahn, Ph.D., M.P.H.
 Susan Ross, Ph.D.

Tab 2654 Protocol

Tab 2655 OBA Summary
 OBA Letter to PI on In-Depth RAC Review and Public Discussion
 Reviews from Dr. Badley, Kahn and Ross
 PI's Response

12:00 PM

Public Comment

Tuesday, June 7, 2011 (continued)

12:05 AM

Minutes

RAC Reviewers: Jeffrey Bartlett, Ph.D.
Joseph Kanabrocki, Ph.D.

Tab 2656 Minutes of the March 8, 2011 RAC Meeting

12:15 PM

LUNCH

1:00 PM

Discussion of Human Gene Transfer Protocol #1102-1091 titled: A Phase I Dose Escalation Trial Using In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the B-Cell specific Antigen CD19 for In Vivo Treatment of Residual or Relapsed Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation

PI: Nancy Kernan, M.D., Memorial Sloan-Kettering Cancer Center, New York, NY
Slide Presentation

RAC Reviewers: Donald Kohn, M.D.
Anna Mastroianni, J.D., M.P.H.
John Zaia, M.D.

Tab 2657 Protocol

Tab 2658 OBA Summary
OBA Letter to PI on In-Depth RAC Review and Public Discussion
Reviews from Dr. Kohn, Professor Mastroianni and Dr. Zaia
PI's Response

2:30 PM

Public Comment

2:35 PM

BREAK

2:45 PM

Gene Transfer Safety Assessment Board Report
Slide Presentation

RAC Reviewers: Antonio Chiocca, M.D., Ph.D.
Yuman Fong, M.D.
Donald Kohn, M.D.
Marshall Strome, M.D., M.S.
James Yankaskas, M.D., M.S.
John Zaia, M.D.

Tuesday, June 7, 2011 (continued)

Tab 2671 Responses to M-I-C-1
Protocol List
Protocols Not Selected for In-Depth Review and
Public Discussion

3:45 PM **Discussion of Biocontainment for Scripps Research Institute's
Proposed Research Involving Lassa Viruses**

Presenters: Juan de la Torre, Ph.D., Scripps Research Institute,
La Jolla, CA (*via web conference*)

Slide Presentation

Bernard Roizman, Sc.D., RAC Member

Slide Presentation

Ad hoc: Heinrich Feldmann, M.D., Ph.D., National Institute of
Allergy and Infectious Diseases, NIH, Hamilton, MT

Tab 2659 Background Material

4:45 PM **Discussion of Proposed Changes to the *NIH Guidelines for Research
Involving Recombinant DNA Molecules* Section III-E-1: Research
with Defective Viral Genomes in Tissue Culture**

Presenter: Susan Ross, Ph.D., RAC Member

Slide Presentation

5:45 PM **ADJOURN**

Wednesday, June 8, 2011

8:00 AM **Call to Order and Opening Remarks**

John Zaia, M.D., RAC Chair

8:10 AM **Discussion of Human Gene Transfer Protocol #1104-1101 entitled: *A
Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC ± GM-
CSF in Men with Asymptomatic or Minimally Symptomatic Metastatic,
Castrate-Resistant Prostate Cancer***

PI: James Gulley, M.D., Ph.D., F.A.C.P., National Cancer Institute,
NIH, Bethesda, MD

Slide Presentation

Sponsor: BN ImmunoTherapeutics, Inc.

Wednesday, June 8, 2011(continued)

RAC Reviewers: Jeffrey Kahn, Ph.D., M.P.H.
Walter Koch, Ph.D.
John Zaia, M.D.

Ad hoc Reviewer: Howard Scher, M.D., Memorial Sloan-Kettering
Cancer Center, New York, NY (teleconference)

Tab 2660 Protocol

Tab 2661 OBA Summary
OBA Letter to PI on In-Depth RAC Review and
Public Discussion
Reviews from Drs. Kahn, Koch, Scher and Zaia
PI's Response

9:50 AM **Public Comment**

9:45 AM **BREAK**

10:00 AM **Discussion of Human Gene Transfer Protocol #1104-1104 entitled:
*AAV-BDNF Gene Therapy of Obesity***

PIs: Joan Han, M.D., National Institute of Child Health and
Human Development, NIH, Bethesda, MD

Jack Yanovski, M.D., Ph.D., National Institute of Child
Health and Human Development, NIH, Bethesda, MD

Matthew During, M.D., D.Sc., Ohio State University Medical
Center, Columbus, OH

Slide Presentation

RAC Reviewers: Yuman Fong, M.D.
Norman Fost, M.D., M.P.H.
Marcella Sarzotti-Kelsoe, Ph.D.

Ad hoc Reviewers: Rudolph Leibel, M.D., Columbia University,
New York, NY

Edward Oldfield, M.D., F.A.C.S., University of
Virginia, Charlottesville, VA

Tab 2662 Protocol

Wednesday, June 8, 2011(continued)

Tab 2663 OBA Summary
OBA Letter to PI on In-Depth RAC Review and
Public Discussion
Reviews from Drs. Fong, Fost, Leibel, Oldfield and
Sarzotti-Kelsoe
PI's Response

11:45 AM **Public Comment**

11:55 AM **Presentation of Certificates of Appreciation**

Presenter: Amy Patterson, M.D., Office of the Director, NIH

12:15 PM **LUNCH**

1:00 PM **Presentation of Results from Protocol #0710-877 entitled:** *Phase 2 Safety and Efficacy Study Evaluation Glutamic Acid Decarboxylase Gene Transfer to the Subthalamic Nuclei in Subjects with Advanced Parkinson's Disease*

Presenter: Matthew During, M.D., D.Sc., Ohio State University
Medical Center, Columbus, OH
Slide Presentation

Tab 2664 Background Materials

1:45 PM **Discussion of Human Gene Transfer Protocol #1101-1088 entitled:** *Phase I Study of Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients with Malignant Pleural Effusion: Primary, Metastases, and Mesothelioma*

AND

Discussion of Human Gene Transfer Protocol #1101-1089 entitled: *Phase I Trial of Attenuated Vaccinia Virus (GL-ONC1) Delivered Intravenously with Concurrent Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma*

PIs: Valerie Rusch, M.D., Memorial Sloan-Kettering Cancer Center,
New York, NY (for 1101-1088)

Loren Mell, M.D., University of California, San Diego School
of Medicine, San Diego, CA (for 1101-1089)

Sponsor: Genelux Corporation
Slide Presentations: Harrington, Rusch, Mell

RAC Reviewers: David Ornelles, Ph.D.
Bernard Roizman, Sc.D.
Marshall Strome, M.D.
James Yankaskas, M.D., M.S.

Tab 2665 Protocols

Tab 2666 OBA Summary
OBA Letter to PI on In-Depth RAC Review and
Public Discussion
Reviews from Drs. Ornelles, Roizman, Strome and
Yankaskas
PIs' Responses

3:30 PM **Public Comment**

3:35 PM **BREAK**

3:50 PM **Discussion of Human Gene Transfer Protocol #1103-1095 entitled: *A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients with Malignant Gliomas Expressing EGFRvIII***

PI: Steven Rosenberg, M.D., Ph.D., National Cancer Institute, NIH,
Bethesda, MD
Slide Presentation

RAC Reviewers: Andrew Badley, M.D.
Antonio Chiocca, M.D., Ph.D.
Hung Fan, Ph.D.

Tab 2667 Protocol

Tab 2668 OBA Summary
OBA Letter to PI on In-Depth RAC Review and
Public Discussion
Reviews from Drs. Badley, Chiocca and Fan
PI's Response

5:30 PM **Public Comment**

5:35 PM **ADJOURN**

Thursday, June 9, 2011

8:00 AM **Call to Order and Opening Remarks**

John Zaia, M.D., RAC Chair

Thursday, June 9, 2011(continued)

8:05 AM **Discussion of Human Gene Transfer Protocol #1104-1100 entitled: A Phase I Study of the Treatment of Recurrent Malignant Glioma with rQNestin34.5v2, a Genetically Engineered HSV-1 Virus, and Immunomodulation with Cyclophosphamide**

PI: Antonio Chiocca, M.D., Ph.D., Ohio State University Medical Center, Columbus, OH
Slide Presentation

RAC Reviewers: Yuman Fong, M.D.
 Margaret Mallino, B.S.
 James Yankaskas, M.D., M.S.

Ad hoc Reviewer: Xandra Breakefield, Ph.D., Massachusetts General Hospital Charlestown, MA

Tab 2669 Protocol

Tab 2670 OBA Summary
 OBA Letter to PI on In-Depth RAC Review and Public Discussion
 Reviews from Drs. Breakefield, Fong, Ms. Mallino and Dr. Yankaskas
 PI's Response

9:50 AM **Public Comment**

10:00 AM

Update on Protocol #0707-864 entitled: An open label dose-escalation study of a self complementary adeno-associated viral vector (scAAV2/8-LPI-hFIXco) for gene therapy of hemophilia B

Presenters: Arthur Nienhuis, M.D., St. Jude Children's Research Hospital, Memphis, TN

 Katherine A. High, M.D., Children's Hospital of Philadelphia, Philadelphia, PA (*teleconference*)
Slide Presentation

11:05 AM Public Comment

11:10 AM **ADJOURN**